Investor Overview

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

Shareholder Letter - August 2018

Press Releases

Date Title and Summary
Toggle Summary Rexahn Pharmaceuticals Streamlines Operations and Provides Update on Pipeline
ROCKVILLE, Md. , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced an operational restructuring that will
Toggle Summary Rexahn Pharmaceuticals Appoints Gil Price to its Board of Directors
ROCKVILLE, Md. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced the appointment of Gil Price , M.D.
Toggle Summary Rexahn Pharmaceuticals Announces Leadership Transition
Douglas Swirsky Assumes Role of Chief Executive Officer ROCKVILLE, Md. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative therapies to improve outcomes in cancers that are difficult to treat, today

Events & Presentations

Date Event Details
Summary Toggle Oct 2 - Oct 3, 2018
Title:  RX-3117, A NOVEL, ORAL NUCLEOSIDE ANALOG, IN COMBINATION WITH NAB-PACLITAXEL (NAB-PAC) IN FIRST-LINE METASTATIC PANCREATIC CANCER (MET-PC): SAFETY, TOLERABILITY AND PRELIMINARY RESPONSES   [View Poster]

Location

National Institutes of Health in Bethesda, Maryland
Summary Toggle Sep 6, 2018
9:35 AM EDT
Sep 6, 2018 9:35 AM EDT 09/06/18
Summary Toggle Jun 1-5, 2018 Jun 1, 2018 06/01/18

Title:   Preliminary Results From an Ongoing Phase 2a Study of RX, an Oral Nucleoside Analogue to Treat Advanced Urothelial Cancer (aUC)  [View Poster]

Title:  Preliminary Report of A Phase 1b/2a Trial, An Oral Inhibitor of Phosphorylated P68 (P-p68),  Which Mediates β-catenin Nuclear Translocation in Advanced Triple-Negative Breast Cancer (TNBC)    [View Poster]



©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy